Condition: Acute Coronary Syndromes (ACS) · Coronary Artery Disease (CAD) · Sponsor: SUK MIN SEO
This study evaluates whether fexuprazan is effective in preventing upper gastrointestinal bleeding and related upper gastrointestinal clinical events in high bleeding risk patients who require dual antiplatelet therapy after coronary stent implantation. A total of 400 participants at a single center will be randomly assigned in a 1:1 ratio within 48 hours after stent implantation to receive either fexuprazan 40 milligrams or lansoprazole 30 milligrams once daily for 6 months. The study will compare upper gastrointestinal clinical events during follow-up
This description comes directly from the study's public registry record.
SUK MIN SEO, MD, PhD · 82+10-9090-8491 · ssm530@catholic.ac.kr
YUN JU KANG, CRC · 82+10-7358-5252 · yunju423@naver.com
Always discuss trial participation with your own doctor first.
| The Catholic University of Korea, Eunpyeong St. Mary's Hospital | Seoul, Eunpyeong-gu, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07479056